A Phase 4 interventional study of Bempedoic Acid 180 MG Oral Tablet and Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet in Healthy Lactating Women, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-11.
Sponsored by Esperion Therapeutics, Inc. · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to characterize the excretion of bempedoic acid or bempedoic acid and ezetimibe into mature breast milk of healthy lactating women and assess the exposure to the breast fed infant by estimating the daily infant dosage and the relative infant dose (RID) of bempedoic acid or bempedoic acid and ezetimibe in breast milk after 6 consecutive daily doses of bempedoic acid or bempedoic acid/ezetimibe FCDP.
Post marketing approval commitment for the FDA
Esperion Therapeutics, Inc. is the lead sponsor of 24 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bempedoic Acid 180 MG Oral Tablet
Drug: Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet
Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]
Also known as: Nexletol
Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]
Also known as: Nexlizet 180 mg-10 mg
Daily Infant Dose
Daily infant dosage of study drug was calculated for Bempedoic Acid arm and FCDP arm respectively from the cumulative amount of study drug (bempedoic acid or bempedoic acid and ezetimibe) excreted in breast milk over 24 hours.
Time frame: 24 hours post Day 6 dose administration
Relative Infant Dose (RID)
Relevant Infant Dose (RID) (calculated as the ratio of estimated infant daily dose per kg body weight and maternal daily dose per kg of body weight multiplied by 100) was analyzed for the Bempedoic Acid arm and FCDP arm respectively. Maternal dosage is the ratio of bempedoic acid dose or ezetimibe dose administered daily divided by maternal body weight at baseline.
Time frame: 24 hours post Day 6 dose administration
Cumulative Amount of Bempedoic Acid (ETC-1002) and Metabolites (ESP-15228, ETC-1002-Glucuronide) in Breast Milk
Cumulative amount of ETC-1002, ESP-15228, and ETC-1002-glucuronide excreted in breast milk during the 24-hour collection period were analyzed for the Bempedoic Acid arm and FCDP arm respectively.
Time frame: 24 hours post Day 6 dose administration
Cumulative Amount of Ezetimibe (EZE) and Metabolite (EZE-Glucuronide) in Breast Milk
Cumulative amount of Ezetimibe, and EZE-glucuronide excreted in breast milk during 24-hour collection period were analyzed (FCDP arm only).
Time frame: 24 hours post Day 6 dose administration
Maximum Concentrations (Cmax) of Bempedoic Acid and Metabolites in Breast Milk
Cmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively
Time frame: 24 hours post Day 6 dose administration
Cmax of Ezetimibe and Metabolite in Breast Milk
Cmax of Ezetimibe, and EZE-glucuronide analyzed in FCDP arm only.
Time frame: 24 hours post Day 6 dose administration
Time of Maximum Concentration (Tmax) of Bempedoic Acid and Metabolites in Breast Milk
Tmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively
Time frame: 24 hours post Day 6 dose administration
Tmax of Ezetimibe and Metabolite in Breast Milk
Tmax of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.
Time frame: 24 hours post Day 6 dose administration
Area Under the Breast Milk Concentration-time Curve Over the 24-hour Collection Interval (AUC24h) of Bempedoic Acid and Metabolites in Breast Milk
AUC24h of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.
Time frame: 24 hours post Day 6 dose administration
AUC24h of Ezetimibe and Metabolite in Breast Milk
AUC24h of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.
Time frame: 24 hours post Day 6 dose administration
Average Concentration (Cavg) of Bempedoic Acid and Metabolites in Breast Milk
Cavg (defined as AUC24h/24h) of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.
Time frame: 24 hours post Day 6 dose administration
Cavg of Ezetimibe and Metabolite in Breast Milk
Cavg of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.
Time frame: 24 hours post Day 6 dose administration
Trough Concentration (Ctrough) of Bempedoic Acid and Metabolites in Breast Milk
Ctrough_milk of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.
Time frame: 24 hours post Day 6 dose administration
Ctrough of Ezetimibe and Metabolite in Breast Milk
Ctrough_milk of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.
Time frame: 24 hours post Day 6 dose administration
Ctrough of Bempedoic Acid and Metabolites in Plasma
Ctrough_plasma of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.
Time frame: 24 hours post Day 6 dose administration
Ctrough of Ezetimibe and Metabolite in Plasma
Ctrough_plasma of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.
Time frame: 24 hours post Day 6 dose administration
Ctrough_milk/Ctrough_plasma (M/P Ratio) of Bempedoic Acid and Metabolites
M/P Ratio of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.
Time frame: 24 hours post Day 6 dose administration
M/P Ratio of Ezetimibe and Metabolite
M/P Ratio of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.
Time frame: 24 hours post Day 6 dose administration
This was a Phase 4, open-label study that estimated the daily infant dosage and relative infant dose (RID) for bempedoic acid and bempedoic acid/ezetimibe fixed combination drug product (FCDP) and characterized the excretion of bempedoic acid (ETC-1002), ezetimibe, and metabolites ESP-15228, ETC-1002-glucuronide, and ezetimibe-glucuronide in the mature breast milk of healthy women.
| Milestone | Bempedoic Acid | Bempedoic Acid/Ezetimibe FCDP |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Daily infant dosage of study drug was calculated for Bempedoic Acid arm and FCDP arm respectively from the cumulative amount of study drug (bempedoic acid or bempedoic acid and ezetimibe) excreted in breast milk over 24 hours.
| Milligrams per day | Bempedoic Acid | Bempedoic Acid (FCDP) | Ezetimibe (FCDP) |
|---|---|---|---|
| Daily Infant Dose | 0.0331 ± 0.0210 | 0.0337 ± 0.0286 | 0.0002 ± 0.0002 |
Relevant Infant Dose (RID) (calculated as the ratio of estimated infant daily dose per kg body weight and maternal daily dose per kg of body weight multiplied by 100) was analyzed for the Bempedoic Acid arm and FCDP arm respectively. Maternal dosage is the ratio of bempedoic acid dose or ezetimibe dose administered daily divided by maternal body weight at baseline.
| Percentage of maternal dose | Bempedoic Acid | Bempedoic Acid (FCDP) | Ezetimibe (FCDP) |
|---|---|---|---|
| Relative Infant Dose (RID) | 0.4790 ± 0.1962 | 0.4678 ± 0.2889 | 0.0370 ± 0.0097 |
Cumulative amount of ETC-1002, ESP-15228, and ETC-1002-glucuronide excreted in breast milk during the 24-hour collection period were analyzed for the Bempedoic Acid arm and FCDP arm respectively.
| Nanograms | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Cumulative Amount of Bempedoic Acid (ETC-1002) and Metabolites (ESP-15228, ETC-1002-Glucuronide) in Breast Milk | 33120.0 ± 21034.11 | 14207.4 ± NA | 20690.5 ± 6554.48 | 33673.4 ± 28635.66 | 770.0 ± NA | 20709.1 ± 16012.78 |
Cumulative amount of Ezetimibe, and EZE-glucuronide excreted in breast milk during 24-hour collection period were analyzed (FCDP arm only).
| Nanograms | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| Cumulative Amount of Ezetimibe (EZE) and Metabolite (EZE-Glucuronide) in Breast Milk | 182.2 ± 154.97 | 983.0 ± 996.16 |
Cmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively
| Nanograms per milliliter | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Maximum Concentrations (Cmax) of Bempedoic Acid and Metabolites in Breast Milk | 118.15 ± 38.91 | NA ± NA | 73.06 ± 56.59 | 107.46 ± 43.19 | NA ± NA | 57.29 ± 56.35 |
Cmax of Ezetimibe, and EZE-glucuronide analyzed in FCDP arm only.
| Nanograms per milliliter | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| Cmax of Ezetimibe and Metabolite in Breast Milk | 0.63 ± 44.29 | 2.93 ± 54.02 |
Tmax of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively
| Hours | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Time of Maximum Concentration (Tmax) of Bempedoic Acid and Metabolites in Breast Milk | 2.94 (2.8 to 6.0) | NA (NA to NA) | 8.92 (5.7 to 12.0) | 2.93 (2.8 to 8.9) | NA (NA to NA) | 8.93 (5.8 to 19.7) |
Tmax of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.
| Hours | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| Tmax of Ezetimibe and Metabolite in Breast Milk | 2.93 (2.8 to 6.0) | 5.88 (2.8 to 8.9) |
AUC24h of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.
| Hours*nanograms per milliliter | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Area Under the Breast Milk Concentration-time Curve Over the 24-hour Collection Interval (AUC24h) of Bempedoic Acid and Metabolites in Breast Milk | 1765.86 ± 40.88 | NA ± NA | 1308.84 ± 56.24 | 1618.25 ± 39.67 | NA ± NA | 1057.69 ± 43.21 |
AUC24h of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.
| Hours*nanograms per milliliter | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| AUC24h of Ezetimibe and Metabolite in Breast Milk | 7.79 ± 38.29 | 41.09 ± 66.10 |
Cavg (defined as AUC24h/24h) of ETC-1002, ESP-15228, and ETC-1002-glucuronide in Breast Milk were analyzed for Bempedoic Acid arm and FCDP arm respectively.
| Nanograms per milliliter | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Average Concentration (Cavg) of Bempedoic Acid and Metabolites in Breast Milk | 74.181 ± 40.75 | NA ± NA | 54.982 ± 55.98 | 67.848 ± 39.77 | NA ± NA | 44.346 ± 43.42 |
Cavg of Ezetimibe and EZE-glucuronide in Breast Milk were analyzed for FCDP arm only.
| Nanograms per milliliter | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| Cavg of Ezetimibe and Metabolite in Breast Milk | 0.327 ± 38.41 | 1.723 ± 66.03 |
Ctrough_milk of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.
| Nanograms per milliliter | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Trough Concentration (Ctrough) of Bempedoic Acid and Metabolites in Breast Milk | 50.58 ± 47.59 | NA ± NA | 45.55 ± 62.72 | 58.60 ± 53.36 | NA ± NA | 39.32 ± 51.81 |
Ctrough_milk of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.
| Nanograms per milliliter | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| Ctrough of Ezetimibe and Metabolite in Breast Milk | 0.25 ± 38.66 | 1.33 ± 82.37 |
Ctrough_plasma of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.
| Nanograms per milliliter | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Ctrough of Bempedoic Acid and Metabolites in Plasma | 10025.6 ± 25.46 | 1862.4 ± 34.04 | 4904.9 ± 35.65 | 9665.9 ± 37.95 | 1641.8 ± 20.78 | 4984.7 ± 35.65 |
Ctrough_plasma of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.
| Nanograms per milliliter | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| Ctrough of Ezetimibe and Metabolite in Plasma | 2.29 ± 69.37 | 35.76 ± 77.54 |
M/P Ratio of ETC-1002, ESP-15228, and ETC-1002-glucuronide were analyzed for Bempedoic Acid arm and FCDP arm respectively.
| Ratio | ETC-1002 | ESP-15228 | ETC-1002-Glucuronide | ETC-1002 (FCDP) | ESP-15228 (FCDP) | ETC-1002-Glucuronide (FCDP) |
|---|---|---|---|---|---|---|
| Ctrough_milk/Ctrough_plasma (M/P Ratio) of Bempedoic Acid and Metabolites | 0.005 ± 25.35 | NA ± NA | 0.009 ± 29.05 | 0.006 ± 59.39 | NA ± NA | 0.008 ± 63.91 |
M/P Ratio of Ezetimibe and EZE-glucuronide were analyzed for FCDP arm only.
| Ratio | Ezetimibe | EZE-Glucuronide |
|---|---|---|
| M/P Ratio of Ezetimibe and Metabolite | 0.108 ± 62.21 | 0.037 ± 81.68 |
Collected over Up to Day 43. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bempedoic Acid | 0/8 (0%) | 0/8 (0%) | 4/8 (50%) |
| Bempedoic Acid / Ezetimibe FCDP | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | Bempedoic Acid | Bempedoic Acid / Ezetimibe FCDP |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/8 | 2/8 |
| VomitingGastrointestinal disorders | 0/8 | 2/8 |
| AstheniaGeneral disorders | 0/8 | 2/8 |
| HeadacheNervous system disorders | 2/8 | 0/8 |
| Abdominal discomfortGastrointestinal disorders | 1/8 | 1/8 |
| Abdominal pain upperGastrointestinal disorders | 0/8 | 1/8 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 |
| RhinitisInfections and infestations | 1/8 | 0/8 |
| Alanine aminotransferase increasedInvestigations | 0/8 | 1/8 |
| Aspartate aminotransferase increasedInvestigations | 0/8 | 1/8 |
Full Analysis Set comprised of all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(Years) | Bempedoic Acid | Bempedoic Acid/Ezetimibe FCDP | Total |
|---|---|---|---|
| Mean | 33.5 ± 4.17 | 27.1 ± 4.09 | 30.3 ± 5.17 |
| Sex: Female, Male(Participants) | Bempedoic Acid | Bempedoic Acid/Ezetimibe FCDP | Total |
|---|---|---|---|
| Female | 8 | 8 | 16 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Bempedoic Acid | Bempedoic Acid/Ezetimibe FCDP | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 3 |
| Not Hispanic or Latino | 8 | 5 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Bempedoic Acid | Bempedoic Acid/Ezetimibe FCDP | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 1 | 3 | 4 |
| White | 4 | 3 | 7 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2023 to primary completion in Feb 2024, 6 months.
Results were first posted in Apr 2025, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bempedoic acid